LENZ

-- -- --

From March 31,2026 to June 30,2026 Issuance of common stock under employee stock purchase plan

From December 31, 2024 to December 31, 2025 Exercise of stock options Vesting of early exercised stock options Issuance of common stock through at-the-market offerings, net of issuance costs Exercise of stock warrants Issuance of common stock under employee stock purchase plan

From June 30, 2025 to September 30, 2025 Exercise of stock options Vesting of early exercised stock options

From March 31, 2025 to June 30, 2025 Exercise of stock options Vesting of early exercised stock options Issuance of common stock through at-the-market offerings, net of issuance costs Exercise of stock warrant Issuance of common stock under employee stock purchase plan

From December 31, 2024 to March 31, 2025 Share-based compensation Vesting of early exercised stock options Exercise of stock options and common warrants

From December 31, 2023 to December 31, 2024 Conversion of convertible preferred stock and Class B convertible common stock to common stock as a result of the Merger and reset to par of $0.00001 Issuance of common stock to Graphite stockholders as a result of the Merger Issuance of common stock from private placements, net Exercise of stock options and common warrants Vesting of early exercised stock options

From June 30, 2024 to September 30, 2024 Issuance of common stock from private placement, net Exercise of stock options Vesting of early exercised stock options

From March 31, 2024 to June 30, 2024 Exercise of stock options Vesting of early exercised stock options

From December 31, 2023 to March 31, 2024 Vesting of early exercised stock options Exercise of stock options and common warrants Issuance of common stock from private placement, net Issuance of common stock to Graphite stockholders as a result of the Merger Conversion of convertible preferred stock and Class B convertible common stock to common stock as a result of the Merger and reset to par of $0.00001

LENZ Therapeutics, Inc. announced the completion of its previously announced merger with Graphite Bio, Inc. and Graphite effected a reverse stock split of Graphite’s issued common stock at a ratio of 1:7.

From December 31, 2022 to December 31, 2023 Common stock issued upon exercise of options Repurchase of unvested early exercised shares Common stock issued under ESPP Repurchase of founders' shares

From June 30, 2023 to September 30, 2023 Common stock issued upon exercise of options Repurchase of unvested early exercised shares

From March 31, 2023 to June 30, 2023 Common stock issued upon exercise of options Repurchase of unvested early exercised shares Common stock issued under ESPP Repurchase of founders' shares

From December 31, 2022 to March 31, 2023 Repurchase of unvested early exercised shares

From December 31, 2021 to December 31, 2022 Common shares issued upon exercise of options Common shares issued under ESPP Repurchase of unvested early exercised shares

From June 30, 2022 to September 30, 2022 Common stock issued upon exercise of options Repurchase of unvested early exercised shares

From March 31, 2022 to June 30, 2022 Common stock issued upon exercise of options Common stock issued under ESPP Repurchase of unvested early exercised stock options

From December 31, 2020 to December 31, 2021 Common stock issued upon exercise of options Common stock issued upon early exercise of options Common stock issued under ESPP Issuance of Series A redeemable convertible preferred stock for cash, net of issuance costs of $4 Issuance of Series B redeemable convertible preferred stock for cash, net of issuance costs of $226 Reclassification of tranche liability upon settlement Issuance of common stock in connection with License Agreement with Stanford Repurchase of common stock in connection with terms of License Agreement with Stanford Issuance of common stock upon initial public offering, net of issuance costs Conversion of redeemable convertible preferred stock to common stock at closing of initial public offering Repurchase of unvested early exercised stock options

From June 30, 2021 to September 30, 2021 Issuance of common stock upon initial public offering, net of issuance costs

From March 31, 2021 to June 30, 2021 Conversion of redeemable convertible preferred stock to common stock at closing of initial public offering Common shares issued upon exercise of stock options Issuance of common shares in connection with License Agreement with Stanford Repurchase of common shares in connection with terms of License Agreement with Stanford Issuance of common stock upon initial public offering, net of issuance costs

1.Common stock offered by company 14,000,000 shares 2.The number of shares of common stock to be outstanding immediately after this offering is based on 41,979,002 shares of common stock outstanding